Partial correction of the CFTR-dependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene

Journal of Gene Medicine

Volumn 10, Issue 1, 2008, Pages 51-60

  Mueller, Christian ^a   Torrez, Daniel ^a   Braag, Sofia ^a   Martino, Ashley ^a   Clarke, Tracy ^b   Campbell Thompson, Martha ^b   Flotte, Terence R ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

AAV; ABPA; Allergy; CFTR; Cystic fibrosis; Gene therapy; Th1 Th2

Indexed keywords

ASPERGILLUS FUMIGATUS CRUDE PROTEIN EXTRACT; FUNGAL PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 13; PARVOVIRUS VECTOR; RANTES; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOPULMONARY ASPERGILLOMA; CHEMOSENSITIZATION; CONTROLLED STUDY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; GENE TARGETING; GENE TRANSFER; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE DRUG DOSE; SPLEEN CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CELL PROLIFERATION; COMPLEX MIXTURES; CONCANAVALIN A; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FLUORESCEIN-5-ISOTHIOCYANATE; GENE EXPRESSION REGULATION; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED CFTR; MUTANT PROTEINS; MUTATION; SPLEEN; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ASPERGILLUS FUMIGATUS; MUS;

EID: 38349091329     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1119     Document Type: Article

References (46)

1. Muller C, Braag SA, Herlihy JD, et al. Enhanced IgE allergic response to Aspergillus fumigatus in CFTR -/- mice. Lab Invest 2006; 86: 130-140.
2. Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 2004; 164: 1481-1493.
3. Wainwright B. The molecular pathology of cystic fibrosis. Curr Biol 1991; 1: 80-82.
4. Davidson DJ, Webb S, Teague P, Govan JR, Dorin JR. Lung pathology in response to repeated exposure to Staphylococcus aureus in congenic residual function cystic fibrosis mice does not increase in response to decreased CFTR levels or increased bacterial load. Pathobiology 2004; 71: 152-158.
5. Pier GB. CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection. Curr Opin Microbiol 2002; 5: 81-86.
6. Jiang C, Finkbeiner WE, Widdicombe JH, Miller SS. Fluid transport across cultures of human tracheal glands is altered in cystic fibrosis. J Physiol 1997; 501: 637-647.
7. Widdicombe JH. Regulation of the depth and composition of airway surface liquid. J Anat 2002; 201: 313-318.
8. Li C, Naren AP. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol Ther 2005; 108: 208-223.
9. de Bentzmann S, Roger P, Dupuit F, et al. Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immunol 1996; 64: 1582-1588.
10. Zar H, Saiman L, Quittell L, Prince A. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995, 126: 230-233.
11. Bastonero S, Gargouri M, Ortiou S, Gueant JL, Merten MD. Inhibition by TNF-alpha and IL-4 of cationic lipid mediated gene transfer in cystic fibrosis tracheal gland cells. J Gene Med 2005; 7: 1439-1449.
12. Terheggen-Lagro SW, Rijkers GT, van der Ent CK. The role of airway epithelium and blood neutrophils in the inflammatory response in cystic fibrosis. J Cyst Fibros 2005; 4(Suppl 2): 15-23.
13. Conese M, Copreni E, Di Gioia S, De Rinaldis P, Fumarulo R. Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease. J Cyst Fibros 2003; 2: 129-135.
14. Sagel SD, Accurso FJ. Monitoring inflammation in CF. Cytokines. Clin Rev Allergy Immunol 2002; 23: 41-57.
15. Venkatakrishnan A, Stecenko AA, King G, et al. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 23: 396-403.
16. Berger M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc 2002; 23: 19-25.
17. Xu Y, Clark JC, Aronow BJ, et al. Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency. J Biol Chem 2003; 278: 7674-7682.
18. Knutsen AP, Hutchinson PS, Albers GM, Consolino J, Smick J, Kurup VP. Increased sensitivity to IL-4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Allergy 2004; 59: 81-87.
19. Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204-211.
20. Galietta LJ, Pagesy P, Folli C, et al. IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro. J Immunol 2002; 168: 839-845.
21. Hauber HP, Gholami D, Koppermann G, Heuer HE, Meyer A, Pforte A. Increased expression of Interleukin-13 but not Interleukin-4 in cystic fibrosis patients. J Cyst Fibros 2003; 2: 189-194.
22. Ormerod LP, Thomson RA, Anderson CM, Stableforth DE. Reversible airway obstruction in cystic fibrosis. Thorax 1980; 35: 768-772.
23. Mellis CM, Levison H. Bronchial reactivity in cystic fibrosis. Pediatrics 1978; 61: 446-450.
24. Zimmerman B, Feanny S, Reisman J, et al. Allergy in asthma. I. The dose relationship of allergy to severity of childhood asthma. J Allergy Clin Immunol 1988; 81: 63-70.
25. Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 1356-1362.
26. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 1979; 120: 863-873.
27. Feanny S, Forsyth S, Corey M, Levison H, Zimmerman B. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a secretory immune response to a colonizing organism. Ann Allergy 1988; 60: 64-68.
28. Ip MS, So SY, Lam WK, Yam L, Liong E. High prevalence of asthma in patients with bronchiectasis in Hong Kong. Eur Respir J 1992; 5: 418-423.
29. Milla CE, Wielinski CL, Regelmann WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 1996; 21: 6-10.
30. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999; 115: 364-370.
31. Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Aitken ML. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996; 109: 1536-1540.
32. Mussaffi H, Greif J, Kornreich L, et al. Severe allergic bronchopulmonary aspergillosis in an infant with cystic fibrosis and her asthmatic father. Pediatr Pulmonol 2000; 29: 155-159.
33. Skov M, McKay K, Koch C, Cooper PJ. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005; 99: 887-893.
34. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-457.
35. Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87: 893-910.
36. Galietta LJ, Folli C, Marchetti C, et al. Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-gamma. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1186-1194.
37. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000; 120: 518-525.
38. Stecenko AA, King G, Torii K, et al. Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation 2001; 25: 145-155.
39. Aldallal N, McNaughton EE, Manzel LJ, et al. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 1248-1256.
40. Sirninger J, Muller C, Braag S, et al. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004; 15: 832-841.
41. Grubb BR, Pickles RJ, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371: 802-806.
42. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994; 266: 1705-1708.
43. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100: 2810-2815.
44. Auricchio A, O'Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110: 499-504.
45. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 2004; 114: 997-1008; quiz 1009.
46. Song S, Lu Y, Choi YK, et al. DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc Natl Acad Sci U S A 2004; 101: 2112-2116.